Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.74 Insider Own0.38% Shs Outstand69.39M Perf Week-0.29%
Market Cap798.28M Forward P/E- EPS next Y-0.54 Insider Trans0.00% Shs Float69.12M Perf Month-2.42%
Income-120.18M PEG- EPS next Q0.61 Inst Own0.60% Short Float / Ratio0.02% / 1.64 Perf Quarter-17.71%
Sales234.79M P/S3.40 EPS this Y97.62% Inst Trans- Short Interest0.01M Perf Half Y-1.76%
Book/sh2.40 P/B4.79 EPS next Y-844.32% ROA-19.46% Target Price22.20 Perf Year-18.53%
Cash/sh2.61 P/C4.40 EPS next 5Y- ROE-73.19% 52W Range9.07 - 17.05 Perf YTD-9.56%
Dividend- P/FCF- EPS past 5Y-50.45% ROI-38.82% 52W High-32.53% Beta2.47
Dividend %- Quick Ratio1.30 Sales past 5Y45.34% Gross Margin18.75% 52W Low26.84% ATR0.57
Employees- Current Ratio1.47 Sales Q/Q-73.74% Oper. Margin-60.79% RSI (14)41.88 Volatility2.79% 4.84%
OptionableNo Debt/Eq1.23 EPS Q/Q-143.13% Profit Margin-51.19% Rel Volume0.25 Prev Close11.62
ShortableYes LT Debt/Eq0.86 EarningsNov 20 AMC Payout- Avg Volume7.14K Price11.50
Recom1.00 SMA20-7.57% SMA50-2.91% SMA200-8.72% Volume1,795 Change-1.00%
Date Action Analyst Rating Change Price Target Change
Aug-03-22Initiated H.C. Wainwright Buy $34
Nov-27-23 01:00AM
Nov-15-23 01:30AM
Nov-13-23 01:00AM
Nov-11-23 10:25AM
Nov-10-23 01:00AM
01:00AM Loading…
Nov-09-23 01:00AM
Nov-07-23 01:00AM
Nov-06-23 02:30AM
Oct-25-23 12:15PM
Oct-11-23 11:45AM
Oct-05-23 02:30AM
Sep-27-23 09:33AM
Sep-25-23 01:00AM
Sep-21-23 01:00AM
Sep-07-23 01:00AM
02:30AM Loading…
Sep-06-23 02:30AM
Aug-31-23 01:00PM
Aug-29-23 01:00AM
Aug-28-23 01:00AM
Aug-17-23 01:00AM
Aug-14-23 01:00AM
Aug-03-23 02:30AM
Jul-05-23 02:30AM
Jun-22-23 01:00AM
Jun-21-23 12:15PM
Jun-13-23 01:00AM
Jun-07-23 02:00AM
May-31-23 01:15AM
May-30-23 01:00AM
12:00PM Loading…
May-04-23 12:00PM
Apr-06-23 02:00AM
Mar-31-23 01:00AM
Mar-30-23 01:00AM
Mar-23-23 02:00AM
Mar-06-23 02:00AM
Mar-02-23 01:00AM
Mar-01-23 11:45AM
Feb-20-23 01:00AM
Feb-17-23 01:00AM
Feb-16-23 01:00AM
Feb-14-23 01:00AM
Feb-03-23 12:00PM
Jan-19-23 12:00PM
Jan-05-23 12:00PM
Dec-30-22 12:30PM
Dec-23-22 11:04AM
Dec-21-22 11:45AM
Dec-08-22 10:21AM
Dec-06-22 08:16AM
Dec-05-22 12:00PM
Dec-02-22 10:54AM
Dec-01-22 04:13PM
Nov-29-22 12:00PM
Nov-17-22 01:00AM
Nov-16-22 09:55AM
Nov-10-22 01:00AM
Nov-07-22 11:45AM
Nov-04-22 01:00PM
Oct-12-22 12:00PM
Oct-10-22 01:00AM
Oct-07-22 12:00PM
Oct-04-22 04:00PM
Sep-30-22 01:11AM
Sep-28-22 05:43PM
Sep-26-22 12:39PM
Sep-19-22 07:42AM
Sep-16-22 04:30PM
Sep-08-22 01:00AM
Sep-06-22 01:00AM
Sep-05-22 12:00PM
Aug-29-22 09:03AM
Aug-23-22 11:45AM
Aug-18-22 12:00PM
Aug-15-22 01:00AM
Aug-11-22 07:07AM
Aug-08-22 05:19PM
Aug-04-22 12:00PM
Aug-01-22 11:45AM
Jul-20-22 12:49PM
Jul-05-22 12:00PM
Valneva SE is a specialty vaccine company. The firm focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. It takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. It operates through the following segments: Commercialized products, COVID, Vaccine candidates and Technologies and services. The Commercialized products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment engages in the development, manufacturing and distribution related to COVID-19 vaccine candidate, VLA2001. The Vaccine candidates segment engages in proprietary research and development programs aiming to generate new approvable products in order to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies, excluding COVID-19 vaccine candidate, VLA2001. The Technologies and services segment provides services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.